Board summary
Key figures
36,660
Registered population
82.3% aged 18–64
9.1%
Aged 65+
ICB 21.9% · England 17.9%
15.9%
Ethnic minority (non-White)
5.5% Asian · England 9.6%
9.9%
In IMD quintile 1
ICB 9.2% · England 21.0%
~2,542
Core20 residents (est.)
Resident basis; registered basis ~3,273 · see page 3
2,417
Hypertension register
+15.19% in 3 yrs · England +5.60%
340
SMI register
7.3% of Brighton and Hove (LAD)'s
339
COPD register
Reviews -9.38% in 3 yrs
Forecast to 2030
3,218
Hypertension patients, 2030
+801 on today
73.4%
QRISK ≥20% on statins, 2030
+7.01pp over 3 yrs
2.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Core20 and vaccination gaps concentrate at one practice.
University Of Sussex Health Centre has 19.4% Core20 (3,005 estimated patients) and 28.9% vaccination; Montpelier Surgery 4.2% Core20; Seven Dials Medical Centre 88.5% vaccination.
Screening, asthma reviews and lipid therapy lag England.
Cervical screening in women aged 25-49 is 47.3% (England 66.8%), asthma reviews reach 55.5% (782 unreviewed), and QRISK ≥ 20% lipid therapy is 56.2%.
SMI physical checks and hypertension control beat England.
SMI blood pressure checks reach 84.6% (+14.1 pp over three years, England 83.4%), alongside 70.7% hypertension treatment to target and 60.2% non-frail diabetes HbA1c.
Population, age and ethnicity
Working-age adults form 82.3% of the list while older cohorts and children trail
Across 36,660 registered patients, adults aged 18–64 represent 82.3% (30,167 patients), well above Brighton and Hove (71.4%), NHS Sussex Integrated Care Board (60.5%) and England (62.7%). Patients aged 65+ make up 9.1% (3,322 patients), below the borough (14.0%), ICB (21.9%) and England (17.9%), while children aged 0–17 comprise 8.7% (3,171). For local Census residents, White ethnicity is 84.1% (borough 85.4%, ICB 91.0%, England 81.1%), with an ethnic minority share of 15.9%, including Asian (5.5%) and Black (2.3%) residents. Age reflects registered patients, whereas ethnicity derives from resident Census data.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Brighton and Hove (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Brighton and Hove LA) | 2,702 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.2% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.2% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Brighton and Hove LA) | 1,485 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Brighton and Hove LA) | 19.9 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 9.9% overall but spans a 19.4 pp practice range
The PCN Core20 cohort is 9.9%, below England (21.0%) and Brighton and Hove (17.6%) but above NHS Sussex Integrated Care Board (9.2%). Deprivation is sharply uneven, spanning a 19.4 pp range: University Of Sussex Health Centre records 19.4% (3,005 estimated patients) and Montpelier Surgery records 4.2% (268 patients), while Carden Surgery and Seven Dials Medical Centre record 0.0%. Practice list estimates sum to 3,273 patients versus 2,542 resident decile 1+2 people. Proactive inequalities interventions should concentrate heavily on University Of Sussex Health Centre.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
340
SMI register
0.82% recorded prevalence
117
Learning disability register
0.28% recorded prevalence
10
Care homes, 327 beds
In the PCN catchment
8.2%
Provide unpaid care
Brighton and Hove (LAD), Census 2021
Recorded severe mental illness prevalence is 0.8% (340 patients) and learning disability is 0.3% (117 patients), trailing Brighton and Hove (1.4% and 0.6%), NHS Sussex Integrated Care Board (1.1% and 0.6%) and England (1.0% and 0.6%). The catchment includes 10 care homes with 327 beds, though beds do not establish PCN registrations.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks (84.6%, England 83.4%) and BMI checks (83.9%, England 82.1%) exceed benchmarks, but University Of Sussex Health Centre trails at 73.7% and 68.4% respectively, indicating an outreach priority.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
2,417
Hypertension register
+15.19%
Register growth, 3 yrs
Brighton and Hove (LAD) +7.27% · England +5.60%
+7.33pp
BP control, under 80
≤140/90 · +6.52pp aged 80+
+801
More patients by 2030
Forecast 3,218 (7.72%)
Hypertension case-finding and control
Hypertension register prevalence is 5.8% (2,417 patients; observation period not supplied), below Brighton and Hove (10.5%), NHS Sussex Integrated Care Board (16.3%), and England (15.2%), consistent with 82.3% of patients being aged 18-64. Blood pressure monitoring reaches 91.5% (England 90.0%), and treatment to target is 70.7% (England 70.3%). Among patients under 80, control is 68.9% (England 67.8%), though Carden Surgery records 60.3%. In patients aged 80 and over, control reaches 79.8% against 81.2% in England. While blood pressure monitoring and control exceed England across younger adults, lower control in patients aged 80 and over highlights a priority for targeted clinical reviews.
Lipids and statins
Lipid-lowering therapy reaches 56.2% for QRISK ≥ 20% (England 63.6%), 61.9% in CKD (England 70.3%), and 78.9% in diabetes with CVD (England 84.4%), where uptake fell 2.2% over three years (England +1.0%). Lower therapy rates than England across all three cohorts highlight scope for systematic clinical review.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 25,415 | £2.20 | £2.42 | £1.86 | £55,913 |
| Cardiovascular (all), 2025 | 38,458 | £2.78 | £3.32 | £3.33 | £106,913 |
For lipid-regulating drugs in 2026, 25,415 items were prescribed at £2.20 per item, below Brighton and Hove (£2.47) and NHS Sussex Integrated Care Board (£2.42), but £8,641 more than at England's unit cost (£1.86). Unit-cost differences illustrate indicator variance rather than prescribing efficiency or clinical appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+16.77%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+11.90%
Asthma prevalence, PCN 3-yr % change
Asthma review coverage reached 55.5%, trailing England (65.7%) and Brighton and Hove (60.1%), leaving an estimated 782 of 1,758 register patients without a review despite a 3-year change of +16.8% (England +4.4%). Practice review rates range from 53.2% at Carden Surgery to 77.3% at Montpelier Surgery. Meanwhile, COPD review coverage fell 9.4% over three years (England +2.8%) to 71.1% (England 76.4%) across 339 patients. Review shortfalls across asthma and COPD suggest scope for systematic respiratory recall across member practices.
Cancer register and children's immunisation
The cancer register records 746 patients (1.8% prevalence vs England 3.8%), growing +16.4% over three years (England +9.0%). In childhood immunisations, 6-in-1 coverage at 12 months reaches 95.5%, meeting the 95.0% target. However, MMR dose 2 coverage at age 5 is 78.6% (England 82.8%), sitting 16.4 pp below the 95.0% target, with an 11.9 pp gap between first and second doses.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
At ICB level in 2022, 58.5% of staged cancers in NHS Sussex ICB were diagnosed at stage 1 or 2 (4,799 of 8,209), above England (55.3%) but 16.5 pp below the 75.0% national ambition, with known-stage coverage at 64.3% (8,209 of 12,766). ICB cervical cancer early-stage diagnosis was 58.2% (32 of 55), trailing England (67.6%). At PCN level, cervical screening uptake in women aged 25-49 is 47.3% (England 66.8%), with University Of Sussex Health Centre at 20.9%, contrasting with breast screening coverage at 70.4% (England 69.9%). Low working-age cervical screening uptake may be consistent with wider ICB cervical staging shortfalls, which clinical audit could test.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
Provider waiting times describe the wider system rather than PCN performance. In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the cancer 62-day standard, trailing East Sussex Healthcare NHS Trust (67.0%), Surrey and Sussex Healthcare NHS Trust (70.0%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%) against the 85.0% standard. The trust reached 74.0% on the 28-day faster diagnosis standard and 76.8% on the 31-day combined treatment standard. Diagnostic 6-week-plus waits reached 39.3% for colonoscopy and 45.4% for flexi sigmoidoscopy. These acute delays reflect provider pressures outside direct PCN control.
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 27.53 | 21.40 |
| CT | 8.57 | 0.48 | 18.49 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 43.78 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 15.11 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 21.06 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 28.50 | 23.14 |
| Community services activity | Brighton and Hove residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 23,615 | 309,615 |
| Referrals | 5,590 | 66,930 |
| Patients with a contact | 7,350 | 85,660 |
Community services (residents of Brighton and Hove), Jun 2026 (provisional). In June 2026, community health service contacts for Brighton and Hove residents totalled 23,615, of which 14,325 contacts (60.7%) were with adults aged 65 and over. These provisional borough-level data reflect local authority resident contacts rather than PCN-level activity. High older-age community contacts reflect substantial local demand for complex care outside acute settings.
Practice variation and patient experience
Patient experience varies by 24.4 pp, lowest at University Of Sussex Health Centre
In 2025/26, QOF overall achievement ranged from 79.7% at University Of Sussex Health Centre to 91.5% at Montpelier Surgery (England 92.5%). Vaccination achievement showed a 59.5 pp spread, from 28.9% at University Of Sussex Health Centre to 88.5% at Seven Dials Medical Centre. University Of Sussex Health Centre recorded a 20.4% personalised care adjustment rate versus 10.0% nationally.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Carden Surgery | 115 | 0.0 | 69.0% | 71.2% | 94.2% |
| Seven Dials | 101 | 0.0 | 76.0% | 76.5% | 91.9% |
| Montpelier Surgery | 100 | 4.2 | 87.1% | 76.6% | 90.7% |
| University Of | 61 | 19.4 | 66.8% | 66.2% | 69.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
COPD reviews fell 9.4% over three years despite gains in mental health checks
Over three years, COPD reviews fell 9.4% (England +2.8%) and dementia register prevalence fell 3.7% (England +6.0%), while heart failure reviews rose 3.3% (England +8.7%). Statin treatment for diabetes with cardiovascular disease also declined 2.2% (England +1.0%). Conversely, severe mental illness blood pressure checks rose 14.1 pp to 84.6% (England +4.4 pp), asthma reviews increased 16.8% (England +4.4%), and non-frail diabetes HbA1c control rose 14.0% to 60.2% (England +4.4%). These contrasting trends may reflect differing practice recall processes, which clinical audit would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Dementia register
Heart failure reviews
Diabetes statin (CVD)
Breast screening (53-70)
Asthma reviews
BP check (SMI)
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Brighton and Hove (LAD) | Asset | PCN | Brighton and Hove (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 10 (327 beds) | n/a | Schools (catchment) | 50 | n/a |
| Children's centres | 3 | 14 | Places of worship | 45 | 113 |
| Libraries | 4 | 13 | Homelessness support (VCS) | 0 | no data |
| Primary schools (LA maintained) | 14 | 35 | Primary academies | 1 | 7 |
| Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma review coverage is 55.5% (England 65.7%, Brighton and Hove 60.1%), leaving 782 of 1,758 register patients unreviewed. For discussion: practices could run structured asthma recall using a single clinical template, offering flexible remote or after-work review slots alongside inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pharmacist-led lipid therapy escalation review
Lipid therapy trails England in QRISK ≥ 20% (56.2% vs 63.6%), CKD (61.9% vs 70.3%), and diabetes with CVD (78.9% vs 84.4%; 3-year change -2.2% vs England +1.0%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Targeted cervical screening and immunisation outreach
Cervical screening (25–49 yrs) is 47.3% (England 66.8%; University Of Sussex Health Centre 20.9%), and QOF vaccination achievement spans 59.5 pp (28.9% to 88.5%). For discussion: practices could review recall wording, verify contact details, and offer flexible evening screening and vaccination clinics at University Of Sussex Health Centre. Moderate effort to run.
Evidence base: the cancer register is the cohort for breast, bowel and cervical screening and for urgent suspected-cancer referral; where patients present as emergencies, the screening and referral steps have failed and symptom awareness needs support.
Policy anchor: Core20PLUS5 — 75% of cancers diagnosed at stage 1 or 2 by 2028.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Working-age primary care access (p2) | Aged 18-64 | Neighbourhood health framework | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Targeted SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older adult hypertension review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool MMR second dose recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and survey review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Pharmacist-led lipid therapy escalation review (p12) | Hypertension register · Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Targeted cervical screening and immunisation outreach (p12) | Cancer register · Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) · QOF vaccination and immunisation-domain achievement | Core20PLUS5, 75% stage 1–2 by 2028 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
